- |||||||||| MMV390048 / Medicines for Malaria Venture, DSM265 / Medicines for Malaria Venture, UCT943 / University of Cape Town, Medicines for Malaria Venture
Susceptibility of Plasmodium falciparum isolates from eastern Uganda to antimalarial compounds under development (Convention Center - Hall 4A (4th Floor); In-Person-Only) - Oct 9, 2022 - Abstract #ASTMH2022ASTMH_450;
Three mutations (N957H, I876V and Y883H) in PfPI4K were associated with slightly decreased susceptibility to MMV048 (median IC50 WT vs mutant: 55 nM vs 74 nM for N957H, 61 nM vs 75 nM for I876V, and 60 nM vs 77 nM for Y883H). Overall, Ugandan P. falciparum isolates were highly susceptible to 11 compounds under development as next-generation antimalarials, consistent with a lack of pre-existing or novel resistance-conferring mutations in circulating Ugandan parasites.
- |||||||||| UCT943 / University of Cape Town, Medicines for Malaria Venture
Journal: Automatic reconstruction of metabolic pathways from identified biosynthetic gene clusters. (Pubmed Central) - Apr 13, 2021
In this context, we identified generic knockout targets for the increased production of heterologous compounds. However, as the predicted increase is minor for any of the single-reaction knockout targets, these results indicate that more sophisticated strain-engineering strategies are necessary for the development of efficient BGC expression hosts.
|
